Event Participants
Executives
3 Anurag Surana, Gopikrishnan Sarathy, Harin Kanani
Analysts
11 Abhijit Akella, Ankur Periwal, Arun Prasath, Asit Bhandarkar, Dara Shah, Deepak Poddar, Jason Soans, Rohit Nagraj, Sajal Kapoor, Shivam Gupta, Umang Khanna
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹250 crores | +34% YoY (vs ₹187 cr Q1 FY26); highest-ever quarterly revenue in both organolithium and battery chemicals portfolios; volume-led growth |
| Organic Chemicals Revenue | ₹194 crores | +18% YoY; organolithium hit full 300 tpa capacity utilization with pharma, agro, and semiconductor demand drivers |
| Inorganic Chemicals Revenue | ₹57 crores | +158% YoY; standout performance driven by lithium by-product recycling from organolithium and sustained demand |
| Neogen Ionics Revenue | ₹19 crores | vs ₹5 cr in Q1 FY26; delivered over 50% of entire FY26 revenue in three months; largely electrolyte salts for international customers |
| Gross Profit | ₹117 crores | +37% YoY; optimized product mix and cost pass-through arrangements across raw materials, utilities, freight, and packaging |
| EBITDA | ₹48.2 crores | +53% YoY (vs ₹31.5 cr Q1 FY26) |
| EBITDA Margin | 19.3% | +260 bps YoY; expansion achieved despite Dahej rebuild costs, job work expenses, Neogen Ionics initial costs, and freight spikes |
| PAT | ₹17.1 crores | +67% YoY; PAT margin 6.8% |
| Finance Cost | ₹20.8 crores | +64% YoY; higher debt drawdown for Neogen Ionics CapEx, increased working capital intensity, and temporary holding costs pending insurance claim disbursement |
| Depreciation | ₹8.2 crores | +42% YoY due to smaller CapEx additions during the year |
| Insurance Recoveries | ₹164 crores cumulative | Net claim receivable of ₹186 crores on consolidated basis; further recoveries expected under loss-of-profit and other policies |
Geographic & Segment Commentary
Organic Chemicals (Base Business): Generated ₹194 crores revenue, +18% YoY, with organolithium reaching full utilization of the expanded 300 tpa capacity (vs. original 120 tpa). Demand is broad-based across pharma (largest), semiconductors (ramping post-approval), agro, and specialty polymer applications; international customer approvals continuing.
Inorganic Chemicals: Revenue surged 158% to ₹57 crores, benefiting from lithium by-products recycled from organolithium operations alongside sustained demand. This segment is a key contributor to the standalone guidance upgrade.
Battery Chemicals / Neogen Ionics: Delivered ₹19 crores revenue in Q1 FY27 (vs ₹5 cr in Q1 FY26), mainly from electrolyte salts exported to international customers. Four international customers have provisional approval for lithium electrolyte salts, and final site audits from all four electrolyte manufacturers are complete; commercial supplies commence post final plant trial approvals.
Dahej Replacement Plant: Reconstruction is almost complete with trial runs actively underway; commercial production is set to commence within Q2. The rebuilt plant incorporates improvements based on operational experience, expected to strengthen the CSM offering.
Company-Specific & Strategic Commentary
Non-FEOC Strategic Positioning: Neogen is positioned to serve the US Section 45X tax credit-driven shift to non-FEOC, non-PAP compliant supply chains by 2027. Four of the five major US electrolyte manufacturers have approved Neogen's site, with the fifth expected to approve the Pakhajan facility; the company can supply salts, additives, and solvents constituting 70-80% of electrolyte cost.
Battery Ecosystem & Government Support: Ministry of Heavy Industries projects domestic battery demand rising from 33 GWh to 92 GWh by 2027 and 200+ GWh by 2032, with ~63 GWh under development and ~30 GWh expected commissioning in 2026 alone. Government has allocated a 10 GWh ACC PLI re-bidding tranche and proposed a PLI scheme for battery components to incentivize raw material localization; Neogen claims to be the only gigascale example of an established local supply chain.
QIP Fundraise & Deleveraging: Board approved raising ₹600 crores via qualified institutional placement (subject to shareholder/regulatory approvals) to deleverage the balance sheet and create headroom for future growth opportunities in battery materials, organolithium, and R&D on novel additives and electrolyte designs.
Morita JV Partnership: Strategic partner Morita remains fully committed to its $20 million equity contribution to the Neogen Ionics JV, expected during Q2-Q3 FY27. Japanese technology (Mitsubishi for electrolyte, Morita for LiPF6) ensures zero China dependency on technology.
Organolithium Capacity Expansion: Management will propose incremental capacity addition (₹10-15 crores CapEx) to the board after one more quarter of demand visibility; the current plant hit peak utilization in Q1, and long-term capacity decisions are expected in H2 FY27. Volumes have grown ~12x in 2-3 years since business acquisition through customer base diversification.
Integrated Annual Report: Company published its first integrated annual report for FY26, incorporating BRSR with reasonable assurance, reflecting commitment to governance and transparency.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Standalone Revenue FY27 | ₹950-1,050 crores | Revised up from ₹875-950 crores; driven by organolithium full utilization, strong organic chemical demand, and inorganic lithium sales; ~₹15 crores of Q1 growth attributable to price increases, remainder volume |
| Base Business Revenue FY28 | ₹1,100-1,200 crores | ~10-11% growth from same capacity; focus on product mix optimization, larger volume molecules, and working capital efficiency; formal guidance closer to year-end |
| Battery Chemicals Revenue FY27 | ₹300 crores | Split: ₹200 crores salts (international non-FEOC shift beginning Q3-Q4 with shipments from Nov-Dec) + ₹100 crores electrolyte (Indian ACC PLI ramp-up); zero revenue assumed from Pakhajan (targeting Q3 completion); buffer maintained with upside possible |
| Battery Chemicals Revenue FY28 | ₹1,000+ crores | Assumes 70-80% salt utilization and 30-50% electrolyte utilization; exact number to be provided later |
| Battery Chemicals Revenue FY29 (full utilization) | ₹2,400-2,900 crores | Current CapEx designed for 30 GWh electrolyte and 40 GWh salts; India domestic demand projected ~7x this capacity over five years, plus international non-FEOC demand |
| Base Business EBITDA Margin FY27 | ~18% ±1.5% | Maintained despite Dahej ramp-up costs and temporary expenses; Q1 came in strong at 19.3% |
| Base Business EBITDA Margin FY28 | 19% ±1% | Optimization of product mix, cost efficiencies, and higher-margin molecules |
| Battery Business ROC | ~20% at full utilization (FY29) | On ~₹1,800 crores CapEx plus working capital; interim EBITDA margin not guided due to lithium price volatility and utilization mix |
| Commissioning Timelines | Electrolyte: H1 FY27; Electrolyte salts: H2 FY27 | Electrolyte mechanical assembly complete, trial runs initiated, product validation with domestic cell manufacturers progressing; Pakhajan targeted for Q3 |
| QIP Proceeds Impact | ₹600 crores fundraise | If fully deployed for debt repayment, annual finance cost savings of ~₹40-50 crores at 8-8.5% interest rates; subject to final allocation across opportunities |
Risks & Constraints
| Risk | Context |
|---|---|
| China spot price differential | Current China spot prices for lithium salts are below contracted formula prices; interim Q2-Q3 sales to US customers may require special pricing below formula levels. Management notes the gap has narrowed significantly versus 2024-25; contracted pricing expected from Q4 FY27 onwards. |
| ACC PLI cell production ramp-up delays | Electrolyte revenue guidance of ₹100 crores depends on Indian gigafactories starting and stabilizing production; cell production startups have historically taken longer than expected due to complexity. Mitigation: Pakhajan salt capacity (zero revenue assumed in FY27 guidance) can offset electrolyte shortfalls; management reduced prior battery guidance last year and built in buffer. |
| Customer qualification timelines | US non-FEOC transition required from January 2027, with shipments from India starting November-December; any delay in customer plant trial completions or qualification processes could push revenue recognition to Q4 or beyond. |
| Working capital intensity | Base business requires 140-160 day working capital cycle due to 200+ molecules and 350-400 customers; over five years, cumulative EBITDA of ₹582 crores translated to negative ₹93 crores operating cash flow. Improvement targeted: 140 days by FY28, with battery business at 90 days; FY29 expected to be first year of strong cash conversion. |
| Geopolitical and supply chain volatility | Persistent geopolitical volatility, elevated shipping freight costs, and uneven end-market demand continue to pressure the global chemical industry; partially mitigated through cost pass-through mechanisms with customers on utilities, freight, and packaging. |
| Technology transition risk | Battery chemistry evolution (sodium-ion, silicon-carbon anodes) discussed by analysts; management states lithium-ion remains most efficient, sodium-ion adoption will be gradual and niche, and existing plant can produce sodium-ion electrolytes; silicon-carbon remains a lithium-ion variant requiring only additive ratio optimization. |
| Peak debt levels | Net debt peaks around ₹1,800 crores pre-QIP; after ₹600 crores fundraise, expected at ₹1,000-1,500 crores (best/worst case), further supported by insurance proceeds and working capital normalization; consolidated debt-to-equity at 1.4x vs standalone 0.68x (pre-QIP). |
Q&A Highlights
Battery Business Scale & Technology Risk
- Question: How large can the battery chemicals opportunity be in five years, and is realistic growth assumption given China's technology restrictions? (Asit Bhandarkar)
- Answer: Current CapEx supports ₹2,400-2,900 crores revenue by FY29, covering 30 GWh electrolyte and 40 GWh salts capacity; Indian demand alone projected ~7x current capacity over five years. No China dependency—Neogen uses Japanese Morita/Mitsubishi technology plus homegrown technology. Lithium-ion remains most efficient; sodium-ion shift would be gradual, niche, and the same plant can produce sodium-ion electrolytes. (Dr. Harin Kanani)
FY27 Battery Revenue Guidance & Pricing Structure
- Question: Could you clarify FY27 battery revenue composition, pricing assumptions, and order firmness? (Arun Prasath)
- Answer: FY27 guidance is ₹300 crores: ₹200 crores salts + ₹100 crores electrolytes, most in H2 as US customers shift from FEOC to non-FEOC suppliers from January. Pricing based on lithium formula assuming $15-25/kg LCE (~$20); lithium is pass-through for both salts and electrolytes. All contract volumes are firm; Q2-Q3 may see spot-linked pricing below formula, but regulated supplies from Q3-Q4 will be formula-based. Pakhajan revenue (targeted Q3 completion) excluded from guidance and can provide upside. (Dr. Harin Kanani)
QIP: Use of Proceeds & Deleveraging
- Question: Is the ₹600 crores QIP primarily for debt repayment, and what is the expected finance cost reduction? (Abhijit Akella)
- Answer: Primarily for deleveraging, but also to prepare for growth opportunities: battery materials PLI, international demand beyond current capacity, organolithium expansion, and R&D on novel additives/electrolyte designs. If fully deployed for repayment, annual interest savings of ~₹40-50 crores at 8-8.5% rates. (Dr. Harin Kanani, confirmed by CFO Gopikrishnan Sarathy)
PLI Scheme & Breakthrough with Chinese-Technology Cell Makers
- Question: How will PLI incentives be shared with customers, and how does Neogen break into cell makers with Chinese technology partners (e.g., Exide, Amara Raja)? (Abhijit Akella)
- Answer: PLI battery component scheme is under government discussion, not finalized; intent is level-playing-field pricing parity with global prices, with benefits passed to customers. Neogen has worked with five of six large gigafactories; validation periods with technology partners typically last 3-6 months post-startup. Combined capacity of six gigafactories exceeds 60 GWh; even 50% utilization reaches Neogen's full electrolyte capacity by FY29. International salt/solvent sales (at 70-80% of value) provide a buffer for any unutilized capacity. (Dr. Harin Kanani)
Salt Capacity Ramp & Incremental Expansion Timeline
- Question: Should salt business hit full utilization next year, and how quickly can incremental salt/additive capacity come online? (Ankur Periwal)
- Answer: FY28 target is 70-80% salt utilization. Incremental capacity of 2,000 tpa salt (Pakhajan) and 500 tpa additives (Dahej) can be operational in ~12-15 months, plus 3-6 months for customer approvals—an 18-24 month cycle from decision. Expansion decisions likely triggered end-FY27 or early-FY28 to serve FY29 demand. (Dr. Harin Kanani)
Organolithium Capacity & CSM Ramp
- Question: What is the timeline for organolithium capacity expansion and CSM scaling? (Ankur Periwal)
- Answer: Q1 was the first quarter at full utilization; board proposal for incremental capacity (₹10-15 crores CapEx) will come after one more quarter of visibility, with long-term capacity decisions in H2 FY27. CSM customers remain engaged; Dahej restart with incorporated improvements will enable re-validation this year and ramp-up next year, with dedicated CSM investment expected by FY29-FY30. (Dr. Harin Kanani)
Working Capital Cycle & Peak Net Debt
- Question: At ₹3,500+ crores consolidated revenue by FY29, what working capital would be required, and what's the peak debt level? (Deepak Poddar)
- Answer: Battery business targeted at 90-day working capital cycle (vs. 140-160 days base business due to 200+ molecules); base business to reach 140 days by FY28 and improve to 110-120 days with larger molecules. Peak net debt of ~₹1,800 crores pre-QIP; post-₹600 crores QIP, net debt expected at ₹1,000-1,500 crores, supported by insurance proceeds and working capital normalization. (Dr. Harin Kanani, CFO Gopikrishnan Sarathy)
US Market Opportunity & Competitive Edge
- Question: Which international market offers the largest opportunity, and what edge does Neogen have in winning global customers? (Shivam Gupta)
- Answer: US is the largest market—four of five major electrolyte makers have approved Neogen's site, with the fifth expected to approve Pakhajan (quoting stable Japanese technology). Neogen sells salts, additives, and solvents (70-80% of electrolyte cost). Advantages: established technology partnerships (Mitsubishi/Morita), faster capacity scale-up (Pakhajan site expandable from 30 GWh to 100 GWh), and more efficient incremental CapEx versus new entrants. (Dr. Harin Kanani)
Operating Cash Flow Conversion Timeline
- Question: When will at least 70% of EBITDA consistently translate to operating cash flow? (Sajal Kapoor)
- Answer: Historical negative operating cash flow reflects growth CapEx cycle, fire impact, and working capital intensity from a 200+ molecule portfolio with INR 350-400 customers. Focus shifts to larger volume molecules (₹100 crores+ scale, targeting ₹1,500 crores single molecule) to improve working capital efficiency; FY2028 targets business optimization, and FY2029—with full battery utilization and optimized base business—should be the first strong cash conversion year, though free cash flow remains subject to growth CapEx. (Dr. Harin Kanani)
Contracted vs. Spot Pricing Model
- Question: How much does spot pricing influence contracted capacity, and will US customers pay a premium over China pricing? (Umang Khanna)
- Answer: From Q4 FY27, majority of sales shift to contracted formula pricing—predictable, lithium-linked with stable conversion margins; spot exposure limited to interim Q2-Q3. US customers pay a fair, consistent price rather than a premium, avoiding extreme China spot volatility; the 45X tax credit non-FEOC requirement makes compliance a precondition for subsidy eligibility, not merely supply diversification. (Dr. Harin Kanani)
Organolithium Demand Drivers & Sustainability
- Question: Is the organolithium demand surge seasonal or sustainable? (Jason Soans)
- Answer: No significant seasonality; growth driven by two years of customer base diversification since business acquisition (from 3-4 customers and one major product to a diversified base), with volumes up ~12x in 2-3 years. Pharma is the largest end-user; semiconductor is ramping post-approval, agro is accelerating, and additional international approvals are in process, supporting further capacity addition. (Dr. Harin Kanani)
Key Takeaway
Neogen Chemicals delivered a strong Q1 FY27 with consolidated revenue of ₹250 crores (+34% YoY)—its highest-ever quarterly revenue in both organolithium and battery chemicals—EBITDA of ₹48.2 crores (+53%, 19.3% margin, +260 bps YoY), and PAT of ₹17.1 crores (+67%). The base business hit full organolithium utilization (300 tpa), driving a standalone guidance raise to ₹950-1,050 crores, while Neogen Ionics generated ₹19 crores (largely salt exports) en route to a ₹300 crores FY27 battery revenue target (₹200 crores salts + ₹100 crores electrolytes). Management guides to ₹2,400-2,900 crores battery revenue at full capacity by FY29, underpinned by US non-FEOC demand, 60+ GWh of Indian gigafactories ramping up, and a proposed battery components PLI. A ₹600 crore QIP will deleverage the balance sheet (net debt to ₹1,000-1,500 crores), and Dahej replacement plant resumes commercial production in Q2 with ₹186 crores insurance receivable pending. Key watch points include ACC PLI ramp-up pace, China spot price differentials versus formula contracts, and working capital conversion improvement targeted for FY29.
Transcript complete. All sections available for summary.